Literature DB >> 30552107

Extreme Adhesion Activity of Amyloid Fibrils Induces Subcutaneous Insulin Resistance.

Makoto Nakamura1, Yohei Misumi2, Toshiya Nomura1, Wakana Oka1, Aito Isoguchi1, Kyosuke Kanenawa1, Teruaki Masuda1, Taro Yamashita1, Yasuteru Inoue1, Yukio Ando1, Mitsuharu Ueda1.   

Abstract

Insulin-derived amyloidoma, also called an insulin ball, is a skin-related complication of insulin therapy caused by repeated insulin injections at the same site, where native folded insulin changes into amyloid fibrils and forms a mass with a granulomatous reaction. Insulin-derived amyloidoma is a clinically important condition because of its association with subcutaneous insulin resistance, but the precise effect and mechanism of the insulin absorption impairment have not been clarified. We generated insulin-derived amyloidomas in mouse skin, with the amyloidomas large enough to perform insulin tolerance tests in the mass by repeated injections of highly concentrated insulin amyloid fibrils. We demonstrated that the insulin-derived amyloidomas inhibit insulin absorption. By simultaneous administration of insulin and insulin amyloid fibrils, we showed that this effect is due to the amyloid fibril itself in the absence of a granulomatous reaction. In vitro studies revealed that insulin amyloid fibrils have extremely strong adhesion to native human insulin and various insulin analogs. Furthermore, we showed that native insulin that had adhered to insulin amyloid forms amyloid fibrils at physiological pH. These results suggest that the extreme adhesion of insulin amyloid to native insulin is the main mechanism of impaired insulin absorption and amyloidoma growth.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30552107     DOI: 10.2337/db18-0846

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

Review 1.  Amyloidoma: a review and case report.

Authors:  Sohil S Desai; Michael G Rizzo; Augustus J Rush; Andrew E Rosenberg; Motasem Al Maaieh
Journal:  Skeletal Radiol       Date:  2020-07-24       Impact factor: 2.199

Review 2.  Engineering biopharmaceutical formulations to improve diabetes management.

Authors:  Caitlin L Maikawa; Andrea I d'Aquino; Rayhan A Lal; Bruce A Buckingham; Eric A Appel
Journal:  Sci Transl Med       Date:  2021-01-27       Impact factor: 17.956

3.  Impact of Insulin-Derived Amyloidosis on Glycemic Control and Insulin Dosing.

Authors:  Aaron Estep; Jarrod Uhrig; Curtis Bower; Robert Jarrett
Journal:  Clin Diabetes       Date:  2022

4.  Insulin amyloid polymorphs: implications for iatrogenic cytotoxicity.

Authors:  Keisuke Yuzu; Mikael Lindgren; Sofie Nyström; Jun Zhang; Wakako Mori; Risako Kunitomi; Terumasa Nagase; Keiichi Iwaya; Per Hammarström; Tamotsu Zako
Journal:  RSC Adv       Date:  2020-10-12       Impact factor: 4.036

5.  Local Insulin-Derived Amyloidosis Model Confronted with Silymarin: Histological Insights and Gene Expression of MMP, TNF-α, and IL-6.

Authors:  Katia Azarfar; Parichehreh Yaghmaei; Mahsa M Amoli; Nasim Hayati-Roodbari; Azadeh Ebrahim-Habibi
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

6.  Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo.

Authors:  Debajyoti Das; Avishek Paul; Sujay Krishna Maity; Subhrangsu Chatterjee; Partha Chakrabarti
Journal:  STAR Protoc       Date:  2021-12-14

7.  Phenolic Preservative Removal from Commercial Insulin Formulations Reduces Tissue Inflammation while Maintaining Euglycemia.

Authors:  Adam Mulka; Brianne E Lewis; Li Mao; Roshanak Sharafieh; Shereen Kesserwan; Rong Wu; Donald L Kreutzer; Ulrike Klueh
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-26

8.  New perspectives on insulin therapy.

Authors:  Eiichi Araki; Hirotaka Araki; Takafumi Senokuchi; Hiroyuki Motoshima
Journal:  J Diabetes Investig       Date:  2020-05-21       Impact factor: 4.232

9.  Determination of amyloid core regions of insulin analogues fibrils.

Authors:  Alexey K Surin; Sergei Yu Grishin; Oxana V Galzitskaya
Journal:  Prion       Date:  2020-01-01       Impact factor: 3.931

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.